Subchronic Toxicity Profile of Ifalmin^®Product Containing Toman Fish Extract (<em>Channa micropeltes</em>) in <em>Rattus Novergicus</em>

Ifalmin®, an oral extract of Channa micropeltes (Toman fish) that have registered on Indonesian FDA (BPOM RI) for herbal medicine. Toman fish is known for anti-inflammatory, antidiabetic, wound-healing, and antioxidant activities, but its safety profile requires verification; therefore, this study evaluated the in vivo subchronic toxicity of Channa micropeltes extract. Male and female Rattus norvegicus were allocated to control (0 mg/kg BW), three treatment groups receiving 270, 540, or 1000 mg/kg BW, and a satellite group given 1000 mg/kg BW, with all doses administered orally once daily for 14 consecutive days; animals were observed and assessed on day 15 after dosing cessation. Subchronic toxicity endpoints included clinical signs, body-weight changes, macropathology, relative organ weights, histopathology of heart, liver, kidneys, spleen, and lungs, and standard biochemical and hematological parameters. Across all dose levels, no treatment related abnormalities or organ damage were detected, and physiological and laboratory measures remained comparable to controls. The no-observed-adverse-effect level (NOAEL) was 1000 mg/kg BW. These findings indicate that Ifalmin derived Channa micropeltes extract is relatively non-toxic under the tested subchronic oral exposure conditions.